Biotech Values

[jaybird249]

PIP up 15% $1.38 should run to $2 by January court date

In 2011, the Biomedical Advanced Research and Development Authority (BARDA) awarded SIGA a base contract for the initial procurement of 1.7 million treatment courses of its smallpox drug. The five-year base contract award is valued at $433 million, of which approximately $412.5 million is for purchase of the product. If you do the math, PIP would be entitled to approximately $200 million. Furthermore, in May 2011, SIGA estimated that if the government were to purchase an additional 12 million treatment courses of its smallpox drug the total value for the current U.S. market, including the initial base contract for 1.7 million courses of therapy, could be approximately $2.8 billion.

Currently PIP only has a little more than 48 million shares outstanding, so the upside is substantial. Even if SIGA does not receive any additional orders beyond the initial BARDA contract for $400 million, PIP stand to potentially receive almost $4 per share in proceeds